Last reviewed · How we verify
BXCL701 plus Pembrolizumab
At a glance
| Generic name | BXCL701 plus Pembrolizumab |
|---|---|
| Also known as | BXCL701 plus Pembro |
| Sponsor | BioXcel Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. (PHASE1, PHASE2)
- Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BXCL701 plus Pembrolizumab CI brief — competitive landscape report
- BXCL701 plus Pembrolizumab updates RSS · CI watch RSS
- BioXcel Therapeutics Inc portfolio CI